uniQure (QURE) News and press releases

HC Wainwright & Co. Reiterates Buy on uniQure, Maintains $25 Price Target

20 Aug 24

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Patrick Trucchio reiterates uniQure (NASDAQ:QURE) with a Buy and maintains $25 price target.

Goldman Sachs Maintains Neutral on uniQure, Raises Price Target to $10

2 Aug 24

News, Price Target, Analyst Ratings

Goldman Sachs analyst Salveen Richter maintains uniQure (NASDAQ:QURE) with a Neutral and raises the price target from $6 to $10.

Cantor Fitzgerald Reiterates Overweight on uniQure, Maintains $24 Price Target

16 Jul 24

News, Price Target, Reiteration, Analyst Ratings

Cantor Fitzgerald analyst Kristen Kluska reiterates uniQure (NASDAQ:QURE) with a Overweight and maintains $24 price target.

Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session

11 Jul 24

News, Intraday Update, Markets, Movers, Trading Ideas

UniQure Soars on New Huntington's Disease Study Data

10 Jul 24

Biotech, Earnings, Earnings Beats, News, Penny Stocks, Small Cap, Markets, Analyst Ratings, Trading Ideas, General

uniQure N.V. (NASDAQ: QURE) surged 76.5% on Jul 9 after it announced updated interim data, including up to 24 months of follow-up data, from 29 treated patients enrolled in the ongoing early to mid-stage studies of AMT-130 for Huntington's disease in the United States and EU.

Why Are UniQure Shares Surging Today?

10 Jul 24

News, Movers

UniQure N.V. (NASDAQ: QURE) shares are skyrocketing Wednesday following the release of promising interim data from its Phase I/II clinical trials of AMT-130, a gene therapy targeting Huntington's disease.

Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

10 Jul 24

News, Intraday Update, Markets, Movers, Trading Ideas

SMART Global Posts Upbeat Results, Joins Aehr Test Systems, MarineMax And Other Big Stocks Moving Higher On Wednesday

10 Jul 24

News, Intraday Update, Markets, Movers, Trading Ideas

Kura Sushi Posts Weak Q3 Results, Joins LegalZoom.com And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

10 Jul 24

News, Pre-Market Outlook, Markets, Movers, Trading Ideas

S&P 500 Edges Higher; Indivior Shares Plummet

9 Jul 24

Earnings, News, Eurozone, Commodities, Intraday Update, Markets, Trading Ideas

Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

9 Jul 24

News, Markets, Movers, Trading Ideas

Crude Oil Down 1%; Soligenix Shares Surge

9 Jul 24

Earnings, News, Eurozone, Commodities, Intraday Update, Markets, Trading Ideas

HC Wainwright & Co. Reiterates Buy on uniQure, Maintains $25 Price Target

9 Jul 24

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Patrick Trucchio reiterates uniQure (NASDAQ:QURE) with a Buy and maintains $25 price target.

Why UniQure Stock Is Soaring

9 Jul 24

News, Movers

UniQure shares are trading higher Tuesday after the company announced updated interim data from its ongoing U.S. and European Phase I/II clinical trials of AMT-130 for the treatment of Huntington's disease. Here's a look at the details:

Dow Falls Over 50 Points; US Small Business Optimism Surges In June

9 Jul 24

Earnings, News, Eurozone, Commodities, Markets, Movers, Trading Ideas

uniQure's Huntington's Disease Gene Therapy Shows Interim Results at 24 Months

9 Jul 24

News

uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced updated interim data including up to 24 months of follow-up data

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

15 Aug 24

Health Care, Press Releases

LEXINGTON, Mass. and AMSTERDAM, Aug. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update

1 Aug 24

Earnings, Press Releases

~ Announced RMAT designation for AMT-130 in Huntington's disease and positive interim Phase I/II data demonstrating the slowing of disease progression and reductions in a key biomarker of neurodegeneration; Meeting with

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen

23 Jul 24

M&A, News, Press Releases

~ uniQure maintains preferential access to industry-leading manufacturing capabilities to support its pipeline of gene therapy candidates ~ ~ Immediate reduction in cash burn, projected to save $40 million annually ~

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington's Disease

9 Jul 24

News, Health Care, Press Releases

~ Achieved statistically significant, dose-dependent, and durable evidence of potential therapeutic benefit; Patients receiving high-dose AMT-130 showed 80% slowing of disease progression in the composite Unified